Literature DB >> 6700383

Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication.

A S Lok, I V Weller, P Karayiannis, D Brown, M J Fowler, J Monjardino, H C Thomas, S Sherlock.   

Abstract

Six patients with chronic hepatitis B virus (HBV)-induced liver disease were treated with human lymphoblastoid interferon. Daily, alternate day or thrice weekly regimens were employed in two, one and three patients respectively. Thrice weekly intra-muscular injections of 7.5 to 10 megaunits of interferon/m2 appeared to be as effective as daily injections in producing inhibition of HBV replication, were associated with fewer side effects and could be continued for up to 3 months. The effectiveness of this regimen in producing long-term inhibition of viral replication must now be determined.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6700383     DOI： 10.1111/j.1600-0676.1984.tb00906.x

Source DB:  PubMed          Journal:  Liver        ISSN： 0106-9543


  12 in total

1.  Effects of interferon-alpha therapy on serum and liver HBV DNA in patients with chronic hepatitis B.

Authors:  S V Feinman; B Berris; R Sooknanan; B Fernandes; S Bojarski
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

Review 2.  Parenterally acquired non-A non-B hepatitis ten years on: advances in diagnosis and therapy.

Authors:  M R Jacyna; H C Thomas
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

3.  Progress in hepatitis B: a 30-year journey through three continents.

Authors:  Anna Suk-Fong Lok
Journal:  Hepatology       Date:  2014-05-28       Impact factor: 17.425

Review 4.  Alpha-interferon treatment in hepatitis B.

Authors:  Aaron Shu Jeng Woo; Raymond Kwok; Taufique Ahmed
Journal:  Ann Transl Med       Date:  2017-04

5.  Antiviral treatment of chronic hepatitis B virus infection.

Authors:  D M Novick; H C Thomas
Journal:  J R Soc Med       Date:  1984-12       Impact factor: 5.344

6.  Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy.

Authors:  Norio Akuta; Fumitaka Suzuki; Akihito Tsubota; Yasuji Arase; Yoshiyuki Suzuki; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Kenji Ikeda; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

7.  Psychosocial impact of chronic infection with hepatitis B virus on British patients.

Authors:  A S Lok; D J van Leeuwen; H C Thomas; S Sherlock
Journal:  Genitourin Med       Date:  1985-08

8.  Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis.

Authors:  Takashi Someya; Kenji Ikeda; Satoshi Saitoh; Masahiro Kobayashi; Tetsuya Hosaka; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Yasuji Arase; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

9.  Glycyrrhizin withdrawal followed by human lymphoblastoid interferon in the treatment of chronic hepatitis B.

Authors:  J Hayashi; W Kajiyama; A Noguchi; K Nakashima; M Hirata; S Hayashi; S Kashiwagi
Journal:  Gastroenterol Jpn       Date:  1991-12

10.  Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B.

Authors:  M G Anderson; T J Harrison; G Alexander; A J Zuckerman; I M Murray-Lyon
Journal:  Gut       Date:  1987-05       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.